WAVEMAN · COMPANY

SABS · Sab Biotherapeutics, Inc.

LIVE

TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475

← ALL COMPANIES

SABS

Name: SAB Biotherapeutics, Inc. (SABS) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

SAB Biotherapeutics, Inc.

PHARMA & BIOTECH · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · CIK 0001833214

SEC FILINGS☆ WATCH

INSIDER NET · 180D

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

13F, latest reported quarter

REVENUE GROWTH

-100.0%

XBRL, annual

NET MARGIN

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

no Form 4 purchases or sales on file

CONGRESS

no member of Congress has reported trading it

FUNDS

59 funds added or opened last quarter

below 52% of Pharma & Biotech

REVENUE

-100.0% year over year

the lowest in Pharma & Biotech

MARGIN

no margin: this company reports no revenue to divide by

BUYBACKS

no share repurchases reported

SHORT

no short interest reported

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

59 funds added or opened positions in the latest 13F quarter, of 94 holders.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN +76.9%

+76.9%12M

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

The complete filing record, in one place.

The record shows 59 funds added last quarter. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

UTHR CPIX MRNA REGN LLY ALNY ELF CITR MDGL DNA VRTX NUVL

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

No insider purchases or sales are on record for SAB Biotherapeutics, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-09-05.

INSIDER

FILED

VALUE

Sullivan Eddie Joe

Chief Executive Officer

BUY

2023-12-07

1,740.0

$1.5K

King Michael

CHIEF FINANCIAL OFFICER

BUY

2023-11-30

5,000.0

$4.5K

Reich Samuel J

Executive Chairman

BUY

2023-11-29

11,000.0

$9.8K

HAMILTON CHRISTINE E

Director

BUY

2022-09-13

10,000.0

$7.3K

Sullivan Eddie Joe

CHIEF EXECUTIVE OFFICER

BUY

2022-09-07

14,000.0

$10.4K

6 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 1 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

Caligan Partners LP

7,967,207.0 sh

$31.1M

Vivo Capital, LLC

7,299,909.0 sh

$28.5M

PERCEPTIVE ADVISORS LLC

6,627,501.0 sh

$25.8M

ADAGE CAPITAL PARTNERS GP, L.L.C.

6,405,553.0 sh

$25.0M

RA CAPITAL MANAGEMENT, L.P.

4,401,500.0 sh

$17.2M

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

FORM 144

No planned-sale notices

No insider has notified an intent to sell. This is the panel to watch after a run-up.

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

Simplify Propel Opportunities ETF

$717.1K POSITION · AS OF 2026-03-31

1.0%

Avantis U.S. Small Cap Equity ETF

$104.8K POSITION · AS OF 2026-02-28

0.0%

Blackstone Alternative Multi-Strategy Fund

$149.3K POSITION · AS OF 2026-03-31

0.0%

Victory Extended Market Index Fund

$15.7K POSITION · AS OF 2026-04-30

0.0%

VANGUARD EXTENDED MARKET INDEX FUND

$1.2M POSITION · AS OF 2026-03-31

0.0%

Fidelity Nasdaq Composite Index Fund

$131.9K POSITION · AS OF 2026-02-28

0.0%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Clinical pipeline

ClinicalTrials.gov · 4 registered trials, 2 still enrolling or running — a status change here is dated weeks before the press release

Phase 1

1 ACTIVE

Phase 2

1 ACTIVE

TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12	2022-12
REVENUE	$0	$1.3M	$2.2M	$23.9M
OPERATING INCOME	$-49.0M	$-42.9M	$-38.1M	$-28.9M
NET INCOME	$13.3M	$-34.1M	$-42.2M	$-18.7M
EPS (DILUTED)	-0.79	-3.68	-7.64	-4.31
OPERATING CASH FLOW	$-44.8M	$-34.3M	$-25.1M	$-23.5M
CASH	$10.5M	$8.9M	$56.6M	$15.0M

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-05 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE